← Oncology Approval Tracker

FDA DECISION ·

Carmustine for Injection (Accord)

carmustine · Accord Healthcare

FDA approvalNew formulationBrain tumors and hematologic malignancies
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Injectable carmustine for palliative treatment in specified primary or metastatic brain tumors and labeled combinations in multiple myeloma, relapsed or refractory Hodgkin lymphoma and relapsed or refractory non-Hodgkin lymphoma.

LAMPGEN ANALYSIS

Why it matters

The product approval covers established carmustine indications across solid and hematologic cancers.

What research teams should watch

Verify the disease-specific combination and product preparation before adopting the formulation.

PRIMARY RECORDS

Sources